GCV News Alert Gabelli Convertible and Income Securities (GCV)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gabelli Convertible and Income Securities (GCV) 6.54 $GCV

Gabelli Convertible and Income Securities Fund Reaffirms Its 8% Distribution Policy and Declares Fourth Quarter Distribution of $0.15 Per Share
Business Wire - Thu Nov 20, 4:20PM CST
The Board of Directors of The Gabelli Convertible and Income Securities Fund Inc. (NYSE:GCV) (the "Fund" reaffirmed its 8% distribution policy and declared a $0.15 per share cash distribution payable on December 19, 2014 to common stock shareholders of record on December 12, 2014. With this fourth quarter distribution, the total distributions from the Fund for 2014 would equate to $0.51 per share, an increase from total distributions paid in 2013 of $0.48 per share. The Fund paid distributions of $0.12 per share in the first, second, and third quarters of 2014.
GCV: 6.54 (+0.02), GBL: 79.47 (-1.00)

Gabelli Convertible and Income Securities Fund announces Q3 distribution of USD0.12 per share
M2 - Fri Aug 22, 3:48AM CDT
The Gabelli Convertible and Income Securities Fund Inc (NYSE:GCV), a diversified, closed-end management investment company, reported on Friday that its board of directors reaffirmed its 8% distribution policy and approved a common stock cash distribution of USD0.12 per share.
GCV: 6.54 (+0.02)

Gabelli Convertible and Income Securities Fund Reaffirms Its 8% Distribution Policy and Declares Third Quarter Distribution of $0.12 Per Share
Business Wire - Thu Aug 21, 2:40PM CDT
The Board of Directors of The Gabelli Convertible and Income Securities Fund Inc. (NYSE:GCV) (the "Fund" reaffirmed its 8% distribution policy and declared a $0.12 per share cash distribution payable on September 23, 2014 to common stock shareholders of record on September 16, 2014.
GCV: 6.54 (+0.02), GBL: 79.47 (-1.00)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Current Market Sentiment on HealthEquity Shares: A Closer Look

Updated Category News Views 113

Understanding HealthEquity's Short Interest Dynamics HealthEquity Inc (NYSE: HQY) has seen a significant decrease in its short percent of float, which recently dropped by 11.68%. As of the last report, the company had approximately 5.26 million shares sold short, representing 7.03% of its regular shares available for trading. This situation also highlights an average...

Continue Reading
Investors Update: Class Action Against Bumble Inc. Soon

Updated Category News Views 104

Update on Class Action Lawsuit Against Bumble Inc. (BMBL) The Law Offices of Frank R. Cruz are reminding investors about an upcoming significant deadline concerning a class action lawsuit against Bumble Inc. This lawsuit affects investors who acquired BMBL securities during the designated Class Period. Understanding the Class Action Lawsuit The class action was initiated...

Continue Reading
Analysis of Williams-Sonoma's Recent Surge and Current Changes

Updated Category News Views 293

Understanding Williams-Sonoma's Recent Stock Movements This week has seen an impressive rise of nearly 30% in shares of Williams-Sonoma, Inc. (NYSE: WSM), but recent trading indicates a slight pullback. Investors are reacting to two key factors: the natural tendency to take profits and the decision of some buyers to exit losing positions as market conditions evolve. The...

Continue Reading
Understanding the Arconic Corporation Class Action Update

Updated Category News Views 139

Overview of the Class Action Lawsuit Against Arconic Corporation Levi & Korsinsky, LLP has recently announced a class action regarding Arconic Corporation (ARNC). This situation affects investors who may have been impacted by alleged securities fraud. The firm aims to represent those who traded Arconic shares during a specified period and seeks to recover losses resulting...

Continue Reading
Cambrex Partners with Lilly to Enhance Biotech Innovations

Updated Category News Views 220

Cambrex's Strategic Collaboration with Eli Lilly Cambrex, a key player in the global contract development and manufacturing organization (CDMO) sector, has announced an exciting new partnership with Eli Lilly and Company to enhance support for biotech collaborators. Through this agreement, Cambrex aims to provide accelerated access to essential clinical development...

Continue Reading